Renal Cell Carcinoma News
Study results suggest that 99mTc-MIBI SPECT/CT use can improve the differentiation between benign and malignant kidney tumors.
Two children with recurrent metastatic, TFE3 fusion-positive RCC that expressed MET experienced "prolonged disease control" following treatment with cabozantinib.
Study findings suggest that BET inhibitors might be a promising avenue of drug-development against RCC.
Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.
Computer-assisted evaluation of tumor response reduced errors and time of evaluation compared with standard-of-care.
Cryoablation was associated with good short-term oncologic control and an excellent safety profile in "healthier" patients.
The understanding of genetic conditions with predisposition to renal cell cancer is critical for developing better therapies.
Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.
Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.
Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.
Patients with kidney tumors with pathology indicating a fumarate hydratase (FH) mutation should be referred for genetic testing.
ASCO published new recommendations for the management of patients with clinically localized small renal masses (SRMs).
Combining dalantercept with axitinib treatment may improve clinical outcomes for previously treated patients with renal cell carcinoma (RCC).
Adjuvant chemotherapy after radical nephroureterectomy (RNU) may improve overall survival compared with observation alone.
Allosteric inhibition of AKT with MK-2206 is not superior to everolimus for the treatment of patients with advanced renal cell carcinoma (RCC).
Among patients with intermediate- or poor-risk metastatic renal cell carcinoma (mRCC), first-line therapy with cabozantinib was superior to standard-of-care.
Among patients with intermediate-risk metastatic clear cell renal cell carcinoma (ccRCC), nephrectomy after upfront pazopanib therapy is feasible.
Sonepcizumab improves overall survival of patients with metastatic renal cell carcinoma (mRCC).
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments
- ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer
- Bladder Cancer: Immunotherapies, Combination Therapies, and Current Research
- Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity
- Nivolumab Fails as Single-agent Treatment for Advanced Uterine Leiomyosarcoma